

Postpartum Cardiovascular Outcomes Among Women With Heart Disease from A Nationwide Study



Fabio Lima, MD, MPH^a, Lizhou Nie, MS^b, Jie Yang, PhD^c, Amanda Owens, BA^d, Neda Dianati-Maleki, MD, MSc^d, Cecilia Avila, MD, MPH^e, and Kathleen Stergiopoulos, MD, PhD^{d,*}

There is limited data on postpartum maternal postpartum major adverse cardiovascular and cerebrovascular events (MACCE) among women with heart disease (HD) in the US. Therefore, we aimed to determine the prevalence and predictors of MACCE in the US. The Nationwide Readmissions Databases (2010 to 2014) were screened for patients with and without HD undergoing delivery. HD subtypes included cardiomyopathy (CDM), congenital heart disease, valvular heart disease, and pulmonary hypertension. Rates and reasons of 42-day readmission were determined using weighted national estimates. Independent predictors of postpartum MACCE were determined using multivariable logistic regression for complex survey data. We found among 15,273,247 patients hospitalized for delivery, 33,827 had HD (CDM 22.78%, congenital heart disease 45.98%, valvular heart disease 24.81%, and pulmonary hypertension 6.41%). Of these, 5.2% of HD patients and 1.4% of No HD were readmitted. MACCE was higher in HD vs No HD (2.68% vs 0.17%, $p < 0.0001$). Median time to MACCE was 5.6 days (interquartile range 3 to 15 days). CDM had >10% readmission at 42 days. Among HD patients, cardiovascular, infectious, hypertensive syndromes, and complications of pregnancy were the most common reasons for 42-day readmission. MACCE predictors in women with HD included HD subtype, age, insurance status, obesity, eclampsia, postpartum hemorrhage, MACCE during delivery, preterm delivery, and thrombotic complications. In conclusion, among a nationwide analysis, postpartum MACCE was more common among patients with HD especially within 1 week of discharge from delivery. Predictors can be easily screened for by clinicians, including presence of any HD, hypertensive syndromes, age, obesity, and obstetrical events during index hospitalization. © 2019 Elsevier Inc. All rights reserved. (Am J Cardiol 2019;123:2006–2014)

Preventable cardiovascular complications and death from pregnancy occur on a global scale, and it is a worldwide priority to reduce maternal mortality and morbidity according the United Nations' Millennium Development Goals.¹ Indeed, the United States as a whole had the second-highest maternal mortality ratio among 31 members of the Organization for Economic Cooperation and Development. The most common causes of maternal mortality in the US appear to be cardiovascular disease, hypertensive disorders, and sepsis.^{2–4} Other investigations suggest that

there are substantial postpartum (within 42 days of delivery) and late (>42 days of delivery) maternal cardiovascular events from direct or indirect obstetric causes than those during pregnancy or labor and delivery.⁵ However, maternal events may be underestimated, likely related to events falling outside the delivery hospitalization, and therefore, not captured.⁶ To date, there is little data on the postpartum cardiovascular events among women with heart disease in the US. Therefore, we sought to determine the contemporary rates, reasons, and predictors of postpartum maternal cardiovascular events in the US.

^aCardiovascular Institute, Warren Alpert Medical School of Brown University, Providence, Rhode Island; ^bDepartment of Applied Mathematics and Statistics, Stony Brook University, Stony Brook, New York; ^cDepartment of Family, Population and Preventive Medicine, Stony Brook University Medical Center, Stony Brook, New York; ^dDepartment of Medicine, Division of Cardiovascular Medicine, State University of New York, Stony Brook University Medical Center, Stony Brook, New York; and ^eDepartment of Obstetrics, Gynecology and Reproductive Medicine, University Medical Center, Stony Brook, New York. Manuscript received December 22, 2018; revised manuscript received and accepted March 7, 2019.

Disclosure: The authors have nothing to disclose declare no conflicts of interest or any relationship to industry.

Funding: We acknowledge the statistical support provided by the Biostatistical Consulting Core of Stony Brook University School of Medicine, Stony Brook, NY.

*Corresponding author: Tel: (631) 444-1066; fax: (631) 444-1054.

E-mail address: Kathleen.Stergiopoulos@stonybrookmedicine.edu (K. Stergiopoulos).

Methods

Data were obtained from the 2010 to 2014 Nationwide Readmission Database (NRD), collected by the Healthcare Cost and Utilization Project (HCUP), the largest, publicly available, inpatient databank in the United States.⁷ The NRD is comprised of multiple HCUP State Inpatient Databases that cover multiple geographically dispersed states and deliver annual information on nearly 15 million unweighted discharges (35 million weighted discharges) each year. As per US Census Bureau statistics, the NRD represents nearly half of all US hospitalizations and the US population.⁸ The NRD uses a unique patient linkage identifier to associate the same patient across multiple hospitalizations across a given state, while maintaining the individual's privacy. These linkage identifiers, however, do

not track a given patient across calendar years (December to January). To better generalize the multiple years of data analysis, the Agency for Healthcare Research and Quality, which oversees HCUP databases, has developed discharge weights for the NRD. Each record was associated with a weight which allows for national estimates. Discharge records related to labor and delivery were included in the study. *International Classification of Diseases, Ninth Revision* (ICD-9) codes were used to determine hospitalizations for delivery, defined as any record with a normal delivery or other indications for care in pregnancy, labor, and delivery-related diagnoses as previously described by our group (Appendix).⁹

From 2010 to 2014, a total of 64,997,906 records of women ≥ 18 years of age were extracted for delivery-related analysis. Deliveries with missing data on death or insurance status were excluded ($n = 196,773$). Patients that died during the index hospitalization were excluded from further analysis ($n = 1,497,326$). Patients were further excluded if they were not delivering or had another delivery record found within 42-days of the index hospitalization, or if the index hospitalization occurred in November or December, or if data on length-of-stay were missing ($n = 56,696,098$). The final analytic cohort was comprised of 6,607,709 (national estimate: $n = 15,273,247$) index hospitalizations for delivery (Figure 1).

The investigative arm of the study included patients with heart disease (HD), which was defined as the presence of pulmonary hypertension (PH), cardiomyopathy (CDM), valvular heart disease (VHD), or congenital heart disease (CHD). ICD-9 diagnosis codes were utilized to determine the presence of heart disease (Appendix). A control group was designated as “no heart disease (No HD)” and was comprised of hospitalization for pregnancy and delivery (none of the previously mentioned cardiac disease codes present). For patients with multiple ICD-9 codes for HD, the HD types were assigned according to the priority rule: CDM > VHD > CHD > PH in order to separate multiple diagnoses. Only a minority of cases (1.5%) had overlapping HD diagnoses. Subtypes of CDM (peripartum,

hypertrophic, and all other) were investigated (data presented in Supplemental tables). For patients with multiple ICD-9 CDM codes, the subtypes were assigned according to the priority rule: peripartum > hypertrophic > all other as previously described.⁹

Demographics (except race, which is not available in the NRD), clinical characteristics, co-morbidities, and other covariates of interest associated with the index hospital admission were extracted from the NRD. Delivery hospital characteristics such as teaching status, location, and region were obtained. The length of stay and total hospital charges (which represent absolute total hospital charge) of both the index and readmission were also extracted.

The primary outcome of interest was 42-day postpartum major adverse cardiovascular and cerebrovascular events (MACCE), defined as a composite of in-hospital death (NRD variable Y/N), cardiac arrest (see Appendix for all ICD9 codes), cardiogenic shock, acute myocardial infarction, heart failure, arrhythmia, cardiac complications of anesthesia or other sedation in labor and delivery, stroke, pulmonary embolism, arterial embolism, atheroembolism, obstetrical pulmonary embolism, and respiratory failure or arrest, acute renal failure. Time to first postpartum MACCE is defined as the difference between the admission date of first postpartum MACCE and the discharge date of index events (derived by adding corresponding length-of-stay to the admission date of index events) within 42 days of index events.

Pregnancy-related covariates during the index hospitalization were examined. Covariates of interest included transient hypertension of pregnancy (ICD-9 codes in Appendix), mild preeclampsia, severe preeclampsia, eclampsia complicating labor and delivery, multiple gestation, gestational diabetes mellitus, delivery type, and antepartum hemorrhage, abruptio placentae, and placenta previa. Complications occurring mainly in the course of labor and delivery were included. The overall rate of and median time to readmission were calculated. If a patient had multiple readmissions within 42 days, only the first was included. Causes of 42-day postpartum MACCE and readmission were classified using ICD-9 codes.




Figure 1. **Patient inclusion and exclusion criteria.** Flowchart of selection criteria for index labor and delivery hospitalizations. NRD = Nationwide Readmissions Database.

Statistical analysis software (SAS) using PROC SURVEYFREQ and SURVEYREG were used to generate estimates for the national populations to compare the distribution of patients' characteristics, complications, comorbidities, obstetric outcomes, during-delivery MACCE, and postpartum MACCE between groups with and without heart diseases, and with different types of heart diseases. Categorical variables are presented as frequencies and percentages; continuous variables are presented as mean \pm standard deviation or median with interquartile range as appropriate. Year and stratum identifiers in the NRD files were used as stratification variables, while hospital identifiers and discharge weight were used as the cluster and weight variable, respectively. Total discharges of each stratum in the original national discharge database were used to calculate finite population correction factors in order to get corrected variance estimate and hence valid inference.¹⁰ In order to correctly account for variations between clusters and make accurate inferences about the national population, all records in the NRD remaining in the analysis and interested subgroup analysis were carried out using the domain options in PROC SURVEYFREQ and SURVEYREG.¹¹

Possible predictors for postpartum MACCE among patients with heart disease were selected using ANOVA under the assumption of unequal variance and Pearson's chi-squared test with p values from Monte Carlo simulation to compare patients' characteristics, complications, comorbidities, obstetric outcomes and during-delivery MACCE between HD patients with and without postpartum MACCE. These possible risk factors were further studied in the final multivariable survey logistic regression model using PROC SURVEYLOGISTIC, which was appropriate to draw conclusions about national populations. Similar models were used to compare the risk of postpartum MACCE between patients with and without HD or patients with a specific HD type and without HD. All adjusted ORs along with corresponding 95% confidence intervals are reported. Statistical significance was set at 0.05 and analysis was done using SAS 9.4 (SAS Institute Inc., Cary, NC).

Results

Among the nationally weighted analytical cohort of 15,273,247 patients hospitalized for delivery, there were 33,827 patients with HD (0.22% of the overall cohort) and 15,239,420 with no HD. Among the HD subtypes, there were 7,708 with CDM (22.78% of HD), 15,556 with CHD (45.98% of HD), 8,394 with VHD (24.81% of HD), and 2,169 with PH (6.41% of HD). Patient characteristics and demographics are described in Table 1. The HD group was older than No HD. The HD group was an overall a sicker cohort with higher rates of medical co-morbidities such as asthma, chronic obstructive pulmonary disease and bronchiectasis, complicated and noncomplicated diabetes mellitus, complicated and essential hypertension, and thyroid disease. The HD group also had higher rates of obesity, tobacco, alcohol and other substance use.

Complications during the index hospitalization for delivery are listed in Table 2. Compared to women with No HD, MACCE was more common in women with HD, predominantly due to higher rates of heart failure, arrhythmia, and respiratory arrest or failure. MACCE rates varied among the HD groups, with the highest rates noted in the CDM and PH groups, followed by VHD and least among patients with CHD.

Obstetric complications during delivery (Table 3) were overall more common among women with HD compared with No HD. Early onset of delivery was over twofold higher among patients with HD. CDM and PH had the highest rates of obstetrical complications during the index hospitalization. Over 10% of CDM and PH groups had severe preclampsia.

The overall median time to postpartum MACCE was 5.6 days (interquartile range 3 to 15 days). Postpartum MACCE was more prevalent among patients with HD compared with No HD, mostly due to heart failure, arrhythmia, and respiratory failure or arrest. Among the subtypes of HD, the CDM group had more than twofold higher postpartum MACCE than the PH group (Table 4 and Figure 2).




Figure 2. **Time to post-partum MACCE.** Kaplan-Meier curves. Numbers in parenthesis represent 95% confidence interval. CHD = congenital heart disease; CDM = cardiomyopathy; MACCE = major adverse cardiovascular and cerebrovascular events; No = no heart disease; PH = pulmonary hypertension; VHD = valvular heart disease.

Table 1
Demographics and clinical characteristics during index hospitalization

| Variable | Heart disease (n = 33,827) | No heart disease (n = 15,239,420) | p value | CDM (n = 7,708) | CHD (n = 15,556) | VHD (n = 8,394) | PH (n = 2,169) | p value |
|-------------------------------------------------------------|-------------------------------|--------------------------------------|---------|--------------------|---------------------|--------------------|--------------------|---------|
| Age (\pm SD) | 28.9 (\pm 0.06) | 28.3 (\pm 0.03) | <0.0001 | 30.2 (\pm 0.10) | 28.1 (\pm 0.08) | 29.1 (\pm 0.11) | 29.9 (\pm 0.22) | <0.0001 |
| Age groups (years): | | | <0.0001 | | | | | <0.0001 |
| <=25 | 10652 (31.49%) | 5269290 (34.58%) | | 1948 (25.27%) | 5622 (36.14%) | 2485 (29.61%) | 597 (27.52%) | |
| 26-35 | 18017 (53.26%) | 8168675 (53.60%) | | 4140 (53.71%) | 8179 (52.58%) | 4569 (54.43%) | 1130 (52.08%) | |
| >=36 | 5158 (15.25%) | 1801455 (11.82%) | | 1620 (21.02%) | 1755 (11.28%) | 1340 (15.96%) | 443 (20.40%) | |
| Insurance Status: | | | 0.0005 | | | | | <0.0001 |
| Medicaid / Medicare | 15202 (44.94%) | 6502901 (42.67%) | | 4102 (53.22%) | 6105 (39.25%) | 3743 (44.59%) | 1252 (57.71%) | |
| Private Insurance | 17001 (50.26%) | 7987874 (52.42%) | | 3205 (41.58%) | 8688 (55.85%) | 4254 (50.68%) | 854 (39.36%) | |
| Other | 1624 (4.80%) | 748646 (4.91%) | | 401 (5.20%) | 764 (4.91%) | 397 (4.72%) | 64 (2.93%) | |
| Asthma | 3072 (9.08%) | 570470 (3.74%) | <0.0001 | 776 (10.07%) | 1338 (8.60%) | 661 (7.87%) | 297 (13.68%) | <0.0001 |
| Chronic Obstructive Pulmonary Disease and Bronchiectasis | 77 (0.23%) | 7025 (0.05%) | <0.0001 | 26 (0.34%) | 27 (0.17%) | 6 (0.07%) | 18 (0.82%) | <0.0001 |
| Diabetes mellitus: | | | <0.0001 | | | | | <0.0001 |
| With complications | 300 (0.89%) | 22678 (0.15%) | | 165 (2.15%) | 55 (0.35%) | 37 (0.44%) | 43 (2.00%) | |
| Without complications | 708 (2.09%) | 121013 (0.79%) | | 319 (4.14%) | 162 (1.04%) | 138 (1.64%) | 89 (4.12%) | |
| Hypertension: | | | <0.0001 | | | | | <0.0001 |
| Essential | 974 (2.88%) | 89000 (0.58%) | | 488 (6.33%) | 154 (0.99%) | 166 (1.98%) | 165 (7.62%) | |
| With complications and secondary type | 560 (1.65%) | 7306 (0.05%) | | 384 (4.99%) | 44 (0.28%) | 70 (0.84%) | 62 (2.84%) | |
| Obesity | 3793 (11.21%) | 800719 (5.25%) | <0.0001 | 1468 (19.04%) | 1112 (7.15%) | 748 (8.91%) | 465 (21.44%) | <0.0001 |
| Smoker | 2871 (8.49%) | 844231 (5.54%) | <0.0001 | 872 (11.31%) | 1157 (7.44%) | 678 (8.08%) | 164 (7.57%) | <0.0001 |
| Alcohol abuse | 100 (0.30%) | 16830 (0.11%) | <0.0001 | 44 (0.57%) | 21 (0.14%) | 24 (0.28%) | 11 (0.52%) | 0.0017 |
| Other substance abuse | 1210 (3.58%) | 255361 (1.68%) | <0.0001 | 460 (5.96%) | 352 (2.26%) | 293 (3.50%) | 105 (4.86%) | <0.0001 |
| Thyroid disorder | 2008 (5.94%) | 461856 (3.03%) | <0.0001 | 588 (7.64%) | 822 (5.28%) | 435 (5.18%) | 163 (7.50%) | <0.0001 |

Table 2
Complications during index hospitalization

| Variable | Heart disease (n = 33,827) | No heart disease (n = 15,239,420) | p value | CDM (n = 7,708) | CHD (n = 15,556) | VHD (n = 8,394) | PH (n = 2,169) | p value |
|-----------------------------------------------|-------------------------------|--------------------------------------|---------|--------------------|---------------------|--------------------|-------------------|---------|
| MACCE: | 6986 (20.65%) | 74828 (0.49%) | <0.0001 | 3804 (49.36%) | 1236 (7.95%) | 1315 (15.66%) | 631 (29.07%) | <0.0001 |
| Death* | 0 (0.0%) | 0 (0.0%) | — | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | — |
| Cardiac arrest | 124 (0.37%) | 587 (0.00%) | <0.0001 | 86 (1.12%) | <10 | 26 (0.31%) | 8 (0.37%) | <0.0001 |
| Cardiogenic shock | 133 (0.39%) | 90 (0.00%) | <0.0001 | 124 (1.61%) | <10 | <10 | <10 | <0.0001 |
| Heart failure | 3294 (9.74%) | 2301 (0.02%) | <0.0001 | 2631 (34.13%) | 154 (0.99%) | 339 (4.04%) | 170 (7.85%) | <0.0001 |
| Acute myocardial infarction | 130 (0.38%) | 348 (0.00%) | <0.0001 | 88 (1.14%) | 11 (0.07%) | 17 (0.20%) | 13 (0.61%) | <0.0001 |
| Arrhythmia | 3138 (9.28%) | 55725 (0.37%) | <0.0001 | 1097 (14.23%) | 976 (6.27%) | 835 (9.95%) | 230 (10.60%) | <0.0001 |
| Cardiac complications of anesthesia in L&D | 27 (0.08%) | 869 (0.01%) | <0.0001 | <10 | <10 | 13 (0.15%) | <10 | <0.0001 |
| Stroke | 121 (0.36%) | 967 (0.01%) | <0.0001 | 41 (0.53%) | 55 (0.35%) | 12 (0.14%) | 14 (0.63%) | 0.2379 |
| Obstetrical pulmonary embolism | 236 (0.70%) | 3067 (0.02%) | <0.0001 | 88 (1.14%) | 32 (0.20%) | 44 (0.52%) | 72 (3.32%) | <0.0001 |
| Pulmonary embolism | 27 (0.08%) | 281 (0.00%) | <0.0001 | 11 (0.14%) | 0 (0.0%) | 12 (0.14%) | <10 | — |
| Respiratory failure/arrest | 1771 (5.24%) | 10251 (0.07%) | <0.0001 | 1208 (15.67%) | 99 (0.64%) | 216 (2.58%) | 248 (11.43%) | <0.0001 |
| Acute renal failure | 457 (1.35%) | 5458 (0.04%) | <0.0001 | 329 (4.27%) | 32 (0.21%) | 43 (0.51%) | 52 (2.40%) | <0.0001 |

Table 3
Obstetrical characteristics and complications during index hospitalization

| Variable | Heart disease (n = 33,827) | No heart disease (n = 15,239,420) | p value | CDM (n = 7,708) | CHD (n = 15,556) | VHD (n = 8,394) | PH (n = 2,169) | p value |
|------------------------------------------------------------------|-------------------------------|--------------------------------------|---------|--------------------|---------------------|--------------------|-------------------|---------|
| Antepartum Hemorrhage, Abruptio Placentae and Placenta Previa | 1009 (2.98%) | 284522 (1.87%) | <0.0001 | 275 (3.57%) | 339 (2.18%) | 284 (3.38%) | 112 (5.14%) | <0.0001 |
| Delivery Type: | | | <0.0001 | | | | | <0.0001 |
| Cesarean | 16603 (49.08%) | 5159752 (33.86%) | | 4838 (62.77%) | 6402 (41.15%) | 3997 (47.61%) | 1366 (62.98%) | |
| Vaginal | 17224 (50.92%) | 10079669 (66.14%) | | 2870 (37.23%) | 9155 (58.85%) | 4397 (52.39%) | 803 (37.02%) | |
| Early onset of delivery | 4883 (14.43%) | 1022066 (6.71%) | <0.0001 | 1665 (21.61%) | 1626 (10.45%) | 1111 (13.23%) | 481 (22.18%) | <0.0001 |
| Eclampsia: | | | <0.0001 | | | | | <0.0001 |
| Eclampsia complicating L&D | 120 (0.36%) | 9836 (0.06%) | | 54 (0.70%) | 11 (0.07%) | 35 (0.42%) | 20 (0.93%) | |
| Mild preeclampsia | 1270 (3.75%) | 334739 (2.20%) | | 516 (6.70%) | 392 (2.52%) | 225 (2.68%) | 136 (6.27%) | |
| Severe preeclampsia | 1840 (5.44%) | 226526 (1.49%) | | 922 (11.96%) | 327 (2.10%) | 362 (4.31%) | 229 (10.56%) | |
| Gestational diabetes mellitus | 1578, 3637 (10.75%) | 504146, 1129894 (7.41%) | <0.0001 | 1257 (16.31%) | 1289 (8.29%) | 699 (8.33%) | 391 (18.04%) | <0.0001 |
| Multiple gestation | 1169 (3.46%) | 271079 (1.78%) | <0.0001 | 405 (5.25%) | 375 (2.41%) | 253 (3.01%) | 137 (6.30%) | <0.0001 |
| Premature Rupture of Membranes | 1716 (5.07%) | 651492 (4.28%) | 0.0003 | 281 (3.64%) | 898 (5.77%) | 429 (5.12%) | 108 (4.97%) | 0.0023 |
| Thrombotic Event | 132 (0.39%) | 5939 (0.04%) | <0.0001 | 61 (0.79%) | 16 (0.10%) | 37 (0.45%) | 18 (0.85%) | <0.0001 |
| Transient hypertension of pregnancy | 1364 (4.03%) | 556299 (3.65%) | 0.0536 | 373 (4.84%) | 536 (3.44%) | 318 (3.79%) | 137 (6.33%) | 0.0014 |
| Uterine rupture | 62 (0.18%) | 9575 (0.06%) | <0.0001 | 23 (0.30%) | 27 (0.17%) | 9 (0.11%) | 4 (0.17%) | <0.0001 |
| Laceration (3rd or 4th degree) | 667 (1.97%) | 338974 (2.22%) | 0.1584 | 108 (1.40%) | 395 (2.54%) | 151 (1.80%) | 13 (0.61%) | 0.0007 |
| Postpartum hemorrhage | 1812 (5.36%) | 440463 (2.89%) | <0.0001 | 519 (6.74%) | 717 (4.61%) | 392 (4.66%) | 184 (8.47%) | <0.0001 |
| Postpartum infection | 573 (1.69%) | 49975 (0.33%) | <0.0001 | 268 (3.47%) | 115 (0.74%) | 90 (1.07%) | 100 (4.63%) | <0.0001 |

Table 4
Postpartum MACCE and readmission rate

| Variable | Heart disease (n = 33,827) | No heart disease (n = 15,239,420) | p value | CDM (n = 7,708) | CHD (n = 15,556) | VHD (n = 8,394) | PH (n = 2,169) | p value |
|--------------------------------------------------------------|-------------------------------|--------------------------------------|---------|--------------------|---------------------|--------------------|-------------------|---------|
| Readmission rate: | | | | | | | | |
| 42-day | 5.2% | 1.4% | <0.0001 | 10.3% | 2.5% | 4.9% | 7.5% | <0.0001 |
| Postpartum MACCE: | 906 (2.68%) | 25660 (0.17%) | <0.0001 | 585 (7.60%) | 92 (0.59%) | 161 (1.92%) | 67 (3.10%) | <0.0001 |
| Death | 24 (0.07%) | 328 (0.00%) | <0.0001 | 19 (0.25%) | <10 | 0 (0.0%) | <10 | — |
| Cardiac arrest | 16 (0.05%) | 275 (0.00%) | <0.0001 | 16 (0.21%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | — |
| Cardiogenic shock | 22 (0.07%) | 190 (0.00%) | <0.0001 | 22 (0.29%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | — |
| Heart failure | 659 (1.95%) | 8385 (0.06%) | <0.0001 | 488 (6.33%) | 54 (0.34%) | 78 (0.93%) | 39 (1.80%) | <0.0001 |
| Acute myocardial infarction | 23 (0.07%) | 736 (0.00%) | <0.0001 | 17 (0.22%) | <10 | 0 (0.0%) | 0 (0.0%) | — |
| Arrhythmia | 267 (0.79%) | 7749 (0.05%) | <0.0001 | 149 (1.94%) | 35 (0.23%) | 68 (0.80%) | 15 (0.69%) | <0.0001 |
| Cardiac complications of anesthesia in labor and delivery | 0 (0.0%) | 21 (0.00%) | — | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | — |
| Stroke | 27 (0.08%) | 1376 (0.01%) | <0.0001 | 16 (0.21%) | <10 | <10 | <10 | 0.0024 |
| Obstetrical pulmonary embolism | 49 (0.14%) | 4341 (0.03%) | <0.0001 | 24 (0.31%) | <10 | 16 (0.19%) | <10 | 0.0477 |
| Pulmonary embolism | 30 (0.09%) | 1138 (0.01%) | <0.0001 | 14 (0.18%) | <10 | 9 (0.11%) | <10 | 0.075 |
| Respiratory failure/arrest | 155 (0.46%) | 4745 (0.03%) | <0.0001 | 115 (1.49%) | 14 (0.09%) | 13 (0.15%) | 14 (0.64%) | <0.0001 |
| Acute renal failure | 115 (0.34%) | 2941 (0.02%) | <0.0001 | 36, 77 (1.00%) | <10 | 20 (0.24%) | 13 (0.62%) | <0.0001 |

Rate of 42-day readmission was low for both patients with HD and No HD, though higher in those with HD. The CDM group had over 10% readmission rate at 42 days (Table 4). Most common primary causes for readmission at 42 days are shown in Figure 3. Among women with HD, cardiovascular causes were the most common reason for readmission at 42 days, followed by infection, complications of pregnancy, obstetrical surgery, or surgical wound, and eclampsia or preeclampsia.

Among the CDM subtypes, peripartum CDM had the highest rates of index hospital MACCE, obstetrical complications, 42-day readmission, and postpartum MACCE (Supplemental Tables 1–4).

Multivariable survey logistic regression modeling of predictors for postpartum MACCE among patients with HD is shown in Table 5. The presence of any HD was associated with over fourfold increased risk of postpartum MACCE. Among the HD subtypes CDM carried the highest risk for postpartum MACCE, followed by VHD, subsequently followed by PH, and lastly CHD. Older age groups (26 to 35 years) was significantly associated with increased risk of postpartum MACCE compared with age <25 years. Insurance status and obesity were other covariates associated with postpartum MACCE. Obstetrical complications during the index hospitalization that were significant predictors for postpartum MACCE included mild preeclampsia, postpartum hemorrhage, early onset of delivery, and thrombotic event.

Discussion

In this contemporary, nationally representative population of patients hospitalized for delivery, we found the rate of postpartum MACCE at 42-days was over 15-fold higher among women with HD compared with those without. Among the subgroups of HD, patients with CDM had the highest rates of postpartum MACCE. Heart failure, arrhythmia, and respiratory complications were the most common components of MACCE noted in the postpartum period. Cardiovascular causes were among the leading reasons for readmission among women with HD, typically within 1 week of discharge. We found the presence of any heart disease (particularly CDM), increased age, insurance status, and obesity predictive of postpartum MACCE at 42-days. Clinical events during the index hospitalization such as mild preeclampsia, postpartum hemorrhage, early onset of delivery, and thrombotic complications during the labor and delivery were predictive of postpartum MACCE. To our knowledge, this is the first study of its kind to investigate the postpartum outcomes of patients with HD and different subgroups of HD.

With the NRD we were able to longitudinally track the same patient to 42-days postdischarge from their corresponding labor and delivery hospitalization. We demonstrated that pregnant women with HD are at increased risk for deterioration requiring re-hospitalization in the postpartum period. Due to the hemodynamic challenges of pregnancy, pregnancy is known to cause or worsen cardiac conditions such as CDM and CHD,^{12–15} with mortality rates of about 10% to 25% within 6 months after diagnosis. Although, because these events can occur outside the

Table 5
Risk of post-partum MACCE among patients with heart disease

| | OR (95% CI) | p value |
|--------------------------------------------------------------------------------------|-------------------|---------|
| Heart disease (vs No HD) | 4.38 (3.88-4.96) | <0.0001 |
| Heart disease subtypes (vs No HD) | | <0.0001 |
| CDM | 5.88 (4.99, 6.93) | |
| PH | 2.95 (2.21, 3.94) | |
| CHD | 2.30 (1.69, 3.12) | |
| VHD | 4.56 (3.46, 5.99) | |
| Heart disease subtypes (vs other subtype): | | <0.0001 |
| CDM (vs CHD) | 5.58 (3.79-8.22) | |
| CDM (vs PH) | 2.17 (1.61-2.92) | |
| CDM (vs VHD) | 2.26 (1.69-3.03) | |
| CHD (vs PH) | 0.39 (0.25-0.60) | |
| CHD (vs VHD) | 0.41 (0.27-0.60) | |
| VHD (vs PH) | 0.96 (0.66-1.39) | |
| Age: | | |
| 26-35 (vs ≤25) | 1.90 (1.47-2.45) | |
| 26-35 (vs ≥36) | 0.94 (0.71-1.24) | |
| ≤25 (vs ≥36) | 0.50 (0.36-0.68) | |
| Insurance: | | <0.0001 |
| Medicaid/Medicare (vs Other) | 1.10 (0.72-1.67) | |
| Medicaid/Medicare (vs Private Insurance) | 1.78 (1.37-2.31) | |
| Other (vs Private Insurance) | 1.62 (1.13-2.33) | |
| Asthma | 1.22 (0.90-1.66) | 0.2070 |
| Diabetes: | | 0.1157 |
| With Complication | 2.14 (0.97-4.71) | |
| With Complication (vs without Complication) | 2.16 (0.96-4.87) | |
| Without Complication | 0.99 (0.49-1.99) | |
| Hypertension: | | 0.5846 |
| Essential Hypertension vs Hypertension with Complications and Secondary Hypertension | 1.13 (0.59-2.17) | |
| Essential Hypertension | 1.29 (0.79-2.11) | |
| Hypertension with Complications and Secondary Hypertension | 1.14 (0.65-1.98) | |
| Obesity | 1.34 (1.03-1.75) | 0.0286 |
| Schizophrenia and Other Psychotic Disorders | 1.59 (0.41-6.10) | 0.5025 |
| Smoking | 1.21 (0.89-1.64) | 0.2221 |
| Substance-related Disorders | 1.05 (0.69-1.62) | 0.8087 |
| Laceration (3rd or 4th Degree) | 0.76 (0.14-4.21) | 0.7529 |
| Postpartum Hemorrhage | 1.43 (1.06-1.94) | 0.0202 |
| Antepartum Hemorrhage, Abruptio Placentae and Placenta Previa | 1.11 (0.65-1.88) | 0.7108 |
| Cesarean (vs Vaginal) | 1.08 (0.84-1.39) | 0.5562 |
| Early Onset of Delivery | 1.32 (1.05-1.65) | 0.0152 |
| Eclampsia: | | 0.0008 |
| Eclampsia Complicating Pregnancy/Childbirth (vs Mild Preeclampsia) | 0.93 (0.23-3.74) | |
| Eclampsia Complicating Pregnancy/Childbirth | 1.82 (0.46-7.20) | |
| Eclampsia Complicating Pregnancy/Childbirth (vs Severe Preeclampsia) | 1.87 (0.46-7.50) | |
| Mild Preeclampsia | 1.95 (1.40-2.72) | |
| Mild Preeclampsia (vs Severe Preeclampsia) | 2.00 (1.34-2.98) | |
| Severe Preeclampsia | 0.97 (0.73-1.30) | |
| Gestational Diabetes Mellitus | 0.82 (0.52-1.28) | 0.3767 |
| Thrombotic Event | 1.98 (1.04-3.78) | 0.0375 |
| Uterine Rupture | 1.95 (0.72-5.28) | 0.1908 |

Note: There are two separate multivariate models listed above separated by the thick borderline.

CDM = cardiomyopathy; CHD = congenital heart disease; MACCE = major adverse cardiovascular and cerebrovascular events; PH = pulmonary hypertension; VHD = valvular heart disease.

hospitalization for delivery, women who deteriorate from CDM or other forms of HD can be missed. This is of concern because regardless of how late these events occur, they are pregnancy-related.

Surveillance data has shown cardiovascular disease to be among the leading causes of postpartum maternal deaths and its incidence rate is increasing.^{16,17} CDM is a

significant contributor to cardiovascular maternal morbidity and mortality in the US⁹. Previous investigations have shown CDM to be associated with approximately 12% of postpartum deaths in the US from 2006 to 2009.^{18,19} Herein, HD of any type was associated with postpartum MACCE, while CDM had the highest risk by nearly sixfold and incurred the highest mortality during readmission. This




Figure 3. **Reasons for 42-day readmission in patients with heart disease after delivery.** The smaller pie chart shows distribution of readmissions for cardiovascular events. AV = aortic valve disorder; CDM = cardiomyopathy; Endocrine = endocrine conditions; GI = gastrointestinal conditions; MR = mitral valve regurgitation; Other CV Diseases = other cardiovascular diseases of mother, postpartum condition, or complication; Psychiatric = psychiatric conditions; SLE = systemic lupus erythematosus.

data should heighten awareness of readmission and postpartum risk in patients with CDM or any HD subtype presenting for labor and delivery.

Previous studies have described a high rate of patients losing insurance coverage in the postpartum periods.²⁰ Nearly half of the HD population in our study was ensured with Medicaid/Medicare and logistic regression modeling noted public, compared with private insurance, was more likely to experience postpartum MACCE. Most practices in the US offer a single follow-up visit at 6-weeks (42 days) postdischarge from delivery.²¹ However, loss of healthcare coverage has been demonstrated previously as a barrier to postpartum follow-up and treatment.^{22,23} This raises concern since patients with HD require more, rather than less, intensive monitoring in the postpartum period. Index hospital complications, clinical characteristics, and demographics could be easily screened for, which represent an opportunity for hospital systems and clinicians to identify patients to track closely in the postpartum period in order to deter complications. A multidisciplinary team, inclusive of cardiology, obstetrics/gynecology, and primary care should be closely involved with following patients early in the postpartum period, as most readmissions occur in the first week postpartum.

Our analysis should be interpreted within the context of several limitations. The retrospective nature of the data collection exposes the data to sampling bias and biases implicit in the limitations of the medical record and possible coding errors. Our assessment of postpartum MACCE only extended up to 42 days from the index hospitalization (delivery) discharge. Due to restrictions in the follow-up analysis in the NRD, a large proportion of records were eliminated from the study analysis, although this is common practice in this type of study.^{24,25} Thus, patients presenting to the hospital beyond this time period were not captured. Since the NRD does not capture data on race, outpatient data, vital status between index hospitalization discharge and readmission, these important data

were unattainable. Unfortunately, out-of-hospital maternal events and mortality were not included. Although coding errors are possible, ICD-9 coding has been shown to be associated with low error rates and hold high specificity and positive predictive value among cardiovascular conditions.^{26–30}

In a contemporary, nationwide cohort of pregnant patients with HD and no HD, postpartum MACCE at 42-days was found to be over 15-fold higher among women with HD compared with those without. Median time to cardiovascular events occurred within 1 week of discharge. Patients with cardiomyopathy incurred the highest rate of postpartum MACCE among all studied subgroups. The HD subtype, age, insurance status, obesity, mild preeclampsia, postpartum hemorrhage, early onset of delivery, and thrombotic complications during the labor and delivery predicted postpartum MACCE among patients with HD. These risk factors can be screened for by clinicians during the index-hospitalization for labor and delivery and efforts aimed at monitoring these patients closely after hospital discharge should be implemented.

Supplementary materials

Supplementary material associated with this article can be found in the online version at <https://doi.org/10.1016/j.amjcard.2019.03.012>.

1. Improve Maternal Health. UN Millennium Developmental Goals. 2015. [http://www.un.org/millenniumgoals/2015_MDG_Report/pdf/MDG%202015%20rev%20\(July%201\).pdf](http://www.un.org/millenniumgoals/2015_MDG_Report/pdf/MDG%202015%20rev%20(July%201).pdf). Accessed on July 11, 2018.
2. Roos-Hesslink JW, Ruys TP, Stein JI, Thilen U, Webb GD, Niwa K, Kaemmerer H, Baumgartner H, Budts W, Maggioni AP, Tavazzi L, Taha N, Johnson MR, Hall R. Outcome of pregnancy in patients with structural or ischaemic heart disease: results of a registry of the European Society of Cardiology. *Eur Heart J* 2013;34:657–665.
3. Berg CJ, Callaghan WM, Syverson C, Henderson Z. Pregnancy-related mortality in the United States, 1998 to 2005. *Obstet Gynecol* 2010;116:1302–1309.

4. Weiss BM, von Segesser LK, Alon E, Seifert B, Turina MI. Outcome of cardiovascular surgery and pregnancy: a systematic review of the period 1984-1996. *Am J Obstet Gynecol* 1998;179:1643-1653.
5. Hoyert D. Maternal mortality and related concepts. National Center for Health Statistics. *Vital Health Stat* 2007. https://www.cdc.gov/nchs/data/series/sr_03/sr03_033.pdf. Accessed September 20, 2018.
6. World Health Organization. Classifications. <http://who.int/classifications/icd/en>. Accessed July 11, 2018.
7. Nationwide Inpatient Sample (NIS) Healthcare Cost and Utilization Project (HCUP). Agency for Healthcare Research and Quality, 2003-2012. <http://www.hcup-us.ahrq.gov>. Accessed July 11, 2018.
8. NRD Overview. *Healthcare Cost and Utilization Project (HCUP)*. Rockville, MD: Agency for Healthcare Research and Quality, 2017. www.hcup-us.ahrq.gov/nrdoverview.jsp. Accessed November 17, 2017.
9. Lima FV, Parikh PB, Zhu J, Yang J, Stergiopoulos K. Association of cardiomyopathy with adverse cardiac events in pregnant women at the time of delivery. *JACC Heart Fail*. 2015;3:257-266.
10. The SURVEYFREQ Procedure: Specifying the Sample Design. SAS/STAT(R) 13.2 User's Guide. In: http://support.sas.com/documentation/cdl/en/statug/67523/HTML/default/viewer.htm#statug_surveyfreq_details01.htm. Accessed February 16, 2019.
11. West BT, Berglund P, Heeringa SG. A closer examination of subpopulation analysis of complex-sample survey data. *Stata J* 2008;8:520-531.
12. Ruys TP, Cornette J, Roos-Hesslink JW. Pregnancy and delivery in cardiac disease. *J Cardiol* 2013;61:107-112.
13. Siu SC, Sermer M, Colman JM, Alvarez AN, Mercier LA, Morton BC, Kells CM, Bergin ML, Kiess MC, Marcotte F, Taylor DA, Gordon EP, Spears JC, Tam JW, Amankwah KS, Smallhorn JF, Farine D, Sorensen S. Cardiac disease in pregnancy I. Prospective multicenter study of pregnancy outcomes in women with heart disease. *Circulation* 2001;104:515-521.
14. Stergiopoulos K, Shiang E, Bench T. Pregnancy in patients with pre-existing cardiomyopathies. *J Am Coll Cardiol* 2011;58:337-350.
15. Hayward RM, Foster E, Tseng ZH. Maternal and fetal outcomes of admission for delivery in women with congenital heart disease. *JAMA Cardiol* 2017;2:664-671.
16. Creanga AA, Berg CJ, Syverson C, Seed K, Bruce FC, Callaghan WM. Pregnancy-related mortality in the United States, 2006-2010. *Obstet Gynecol* 2015;125:5-12.
17. Creanga AA, Syverson C, Seed K, Callaghan WM. Pregnancy-related mortality in the United States, 2011-2013. *Obstet Gynecol* 2017;130:366-373.
18. Hameed AB, Lawton ES, McCain CL, Morton CH, Mitchell C, Main EK, Foster E. Pregnancy-related cardiovascular deaths in California: beyond peripartum cardiomyopathy. *Am J Obstet Gynecol* 2015;213:379. e371-310.
19. Creanga AA, Berg CJ, Ko JY, Farr SL, Tong VT, Bruce FC, Callaghan WM. Maternal mortality and morbidity in the United States: where are we now. *J Womens Health (Larchmt)* 2014;23:3-9.
20. D'Angelo DV, Williams L, Harrison L, Ahluwalia IB. Health status and health insurance coverage of women with live-born infants: an opportunity for preventive services after pregnancy. *Matern Child Health J* 2012;16(Suppl 2):222-230.
21. Cheng CY, Fowles ER, Walker LO. Continuing education module: postpartum maternal health care in the United States: a critical review. *J Perinat Educ* 2006;15:34-42.
22. Nielsen KK, Kapur A, Damm P, de Courten M, Bygbjerg IC. From screening to postpartum follow-up - the determinants and barriers for gestational diabetes mellitus (GDM) services, a systematic review. *BMC Pregnancy Childbirth* 2014;14:41.
23. Henderson V, Stumbras K, Caskey R, Haider S, Rankin K, Handler A. Understanding factors associated with postpartum visit attendance and contraception choices: listening to low-income postpartum women and health care providers. *Matern Child Health J* 2016;20:132-143.
24. Tripathi A, Abbott JD, Fonarow GC, Khan AR, Barry NGT, Ikram S, Coram R, Mathew V, Kirtane AJ, Nallamothu BK, Hirsch GA, Bhatt DL. Thirty-day readmission rate and costs after percutaneous coronary intervention in the United States: a national readmission database analysis. *Circ Cardiovasc Interv* 2017;10:e005925.
25. Kim LK, Yeo I, Cheung JW, Swaminathan RV, Wong SC, Charitakis K, Adejumo O, Chae J, Minutello RM, Bergman G, Singh H, Feldman DN. Thirty-day readmission rates, timing, causes, and costs after ST-segment-elevation myocardial infarction in the United States: a national readmission database analysis 2010-2014. *J Am Heart Assoc* 2018;7:e009863.
26. Mandawat A, Mandawat MK. Percutaneous coronary intervention after ST-segment elevation myocardial infarction in nonagenarians: use rates and in-hospital mortality. *J Am Coll Cardiol* 2013;61:1207-1208.
27. Chen J, Dharmarajan K, Wang Y, Krumholz HM. National trends in heart failure hospital stay rates, 2001 to 2009. *J Am Coll Cardiol* 2013;61:1078-1088.
28. Austin PC, Daly PA, Tu JV. A multicenter study of the coding accuracy of hospital discharge administrative data for patients admitted to cardiac care units in Ontario. *Am Heart J* 2002;144:290-296.
29. Roberts CL, Bell JC, Ford JB, Hadfield RM, Algert CS, Morris JM. The accuracy of reporting of the hypertensive disorders of pregnancy in population health data. *Hypertens Pregnancy* 2008;27:285-297.
30. Birman-Deych E, Waterman AD, Yan Y, Nilasena DS, Radford MJ, Gage BF. Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. *Med Care* 2005;43:480-485.